학술논문
The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis
Document Type
article
Author
Delia Colombo; Micol Frassi; Giuseppa Pagano Mariano; Enrico Fusaro; Claudia Lomater; Patrizia Del Medico; Florenzo Iannone; Rosario Foti; Massimiliano Limonta; Antonio Marchesoni; Bernd Raffeiner; Ombretta Viapiana; Marco Di Carlo; Rosa Daniela Grembiale; Giuliana Guggino; Paola Faggioli; Enrico Tirri; Roberto Perricone; Pier Carlo Sarzi Puttini; Salvatore De Vita; Fabrizio Conti; Sara Rizzoli; Barbara Roncari; Martina Fiocchi; Roberto Orsenigo; Emanuela Zagni; Collaboration group; Frassi Micol; Caminiti Maurizio; Fusaro Enrico; Lomater Claudia; Del Medico Patrizia; Iannone Fiorenzo; Foti Rosario; Limonta Massimiliano; Marchesoni Antonio; Raffeiner Bernd; Viapiana Ombretta; Grassi Walter; Grembiale Rosa Daniela; Guggino Giuliana; Mazzone Antonino; Tirri Enrico; Perricone Roberto; Sarzi Puttini Pier Carlo; De Vita Salvatore; Conti Fabrizio
Source
Women's Health Reports, Vol 3, Iss 1, Pp 162-171 (2022)
Subject
Language
English
ISSN
2688-4844
Abstract
Background: Phenotypic features and outcome differences between sexes have been reported in psoriatic arthritis (PsA). However, little is known about sex differences in effectiveness of biologics in clinical practice. Methods: Post hoc gender analysis of the CHRONOS, a multicenter, noninterventional, retroprospective Italian real-world study assessing 6-month and 1-year effectiveness of biologics for PsA. Results: Eligible patients were 399, 43.1% men. Sociodemographic characteristics, type of arthritis, baseline Disease Activity Score 28 joints (DAS28), and duration of biologic treatment were rather homogeneous. More men were overweight/obese and naive to biologics. The most frequently used biologics were TNF-inhibitors and secukinumab in both sexes. DAS28 responders were 72.7% (women) and 70.5% (men) at 6 months, and 68.0% in both sexes at 1 year. American College of Rheumatology (ACR) response showed a trend for men versus women to achieve more frequently ACR50 (32.6% vs. 26.5% at 6 months; 34.9% vs. 20.0% at 1 year) and ACR70 (22.3% vs. 12.4% at 6 months and 25.0% vs. 13.0% at 1 year). Global satisfaction with treatment at enrollment and after 6 months was slightly higher among men [mean (standard deviation) Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) score: 68.6 (18.6) and 69.9 (18.2), respectively] than women [65.3 (18.2), 66.2 (18.5)]. Conclusions: Overall response to biologics for PsA was rather favorable. With similar baseline disease severity, men appear to have a somewhat earlier and better response with higher treatment satisfaction.